Search | Clinical Trials Finder

Conditions: Prehypertension
Interventions: Grape Seed Extract, Placebo; Dietary Supplement
Lead sponsor: California Baptist University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Riverside, California

Conditions: Breast Cancer
Interventions: biopsy, magnetic resonance imaging, radiomammography, ultrasound imaging, gadopentetate dimeglumine, chemotherapy; Procedure · Radiation · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more

Conditions: Mental Health Issue, Substance Use Disorders, Postpartum Depression, Postpartum Anxiety
Interventions: Listening to Women & Pregnant and Postpartum People; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10,469 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Asthma
Interventions: electronic medication monitoring system, parent-adolescent communication and problem-solving skills; Device · Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 9 Years to 15 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 2
States / cities: Kansas City, Missouri • Morgantown, West Virginia

Conditions: Rosacea
Interventions: Azelaic acid, Vehicle, Finacea; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 30
States / cities: Fremont, California • Santa Monica, California • Brandon, Florida + 26 more

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more

Conditions: Statin Therapy, Statin Adverse Reaction, Statin
Interventions: Rosuvastatin (Crestor), Placebo; Drug
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam, Questionnaires, Vital Signs, Standard of Care Treatment; Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor: David Hasan; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2), Simvastatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Heart Failure
Interventions: Remote Dielectric Sensing (ReDS) Wearable System; Device
Lead sponsor: Sensible Medical Innovations Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 41
States / cities: Birmingham, Alabama • Hollywood, California • La Jolla, California + 34 more

Conditions: Crohn's Disease
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more

Conditions: Severe Bronchopulmonary Dysplasia
Interventions: Albuterol Sulfate, Sterile Saline; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 1 Year
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Keratosis
Interventions: Aldara (imiquimod) cream, 5%; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more

Conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions: Lumateperone 42 mg, Risperidone 2 mg; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Fluorouracil, Irinotecan, Leucovorin, Lymph Node Biopsy, Magnetic Resonance Imaging, Oxaliplatin, Pembrolizumab, Photodynamic Therapy, Positron Emission Tomography, Questionnaire Administration, Verteporfin; Procedure · Drug · Biological + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions: Sitaxsentan, Bosentan, Ambrisentan; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dysphagia
Interventions: bupivacaine hydrochloride 0.5% solution, 0.9% NaCl solution; Drug
Lead sponsor: Justin Parker Neurological Institute; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Thrombosis
Interventions: alteplase; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 28 Weeks to 66 Weeks
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Stroke Prevention, Blood Pressure Reduction
Interventions: STEP Clinic, Usual Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ulcerative Colitis
Interventions: sterile saline for injection, MDX-1100; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Port Orange, Florida • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Pain
Interventions: OxyCODONE 5 mg Oral Tablet, OxyCODONE 2.5 mg Oral Tablet, Placebo oxyCODONE Oral Tablet, Oxytocin Nasal Spray (48 IU), Placebo Oxytocin Nasal Spray; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, insulin NPH; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more

Conditions: Immune System and Related Disorders
Interventions: Ibuprofen, Compound Exercise of Push-ups, oral placebo; Drug · Behavioral
Lead sponsor: Womack Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Bethesda, Maryland • Fort Bragg, North Carolina

Conditions: Migraine
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 962 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Sherman Oaks, California • Stamford, Connecticut + 20 more

Search by objective public record fields.

Effect of 7 Days of Grape Seed Extract Supplementation on Cold Pressor Test and Muscle Metaboreflex in Individuals With Elevated and Stage 1 Hypertension

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

Improving Maternal Mental Health & SUD Screening and Treatment

Parent-Youth Teamwork in Pediatric Asthma Management

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

DESIFOR-EXPAND (MHIF)

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Aerosolized Albuterol Use in Severe BPD

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Pharmacogenomics in Pulmonary Arterial Hypertension

Anesthetic to Reduce Dysphagia After Anterior Cervical Discectomy and Fusion Surgery

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

STEPs to Blood Pressure Reduction.

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications